Christopher J. Kirk - 24 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-Fact
Issuer symbol
KZR
Transactions as of
24 Jul 2023
Net transactions value
$0
Form type
4
Filing time
26 Jul 2023, 17:05:55 UTC
Previous filing
24 Jul 2023
Next filing
09 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Stock Option (right to buy) Disposed to Issuer -87,500 -100% 0 24 Jul 2023 Common Stock 87,500 $22.85 Direct F1, F2
transaction KZR Stock Option (right to buy) Award +87,500 87,500 24 Jul 2023 Common Stock 87,500 $2.28 Direct F1, F2
transaction KZR Stock Option (right to buy) Disposed to Issuer -125,000 -100% 0 24 Jul 2023 Common Stock 125,000 $3.29 Direct F2, F3
transaction KZR Stock Option (right to buy) Award +125,000 125,000 24 Jul 2023 Common Stock 125,000 $2.28 Direct F2, F3
transaction KZR Stock Option (right to buy) Disposed to Issuer -260,000 -100% 0 24 Jul 2023 Common Stock 260,000 $5.45 Direct F2, F4
transaction KZR Stock Option (right to buy) Award +260,000 260,000 24 Jul 2023 Common Stock 260,000 $2.28 Direct F2, F4
transaction KZR Stock Option (right to buy) Disposed to Issuer -170,000 -100% 0 24 Jul 2023 Common Stock 170,000 $14.55 Direct F2, F5
transaction KZR Stock Option (right to buy) Award +170,000 170,000 24 Jul 2023 Common Stock 170,000 $2.28 Direct F2, F5
transaction KZR Stock Option (right to buy) Disposed to Issuer -190,000 -100% 0 24 Jul 2023 Common Stock 190,000 $6.84 Direct F2, F6
transaction KZR Stock Option (right to buy) Award +190,000 190,000 24 Jul 2023 Common Stock 190,000 $2.28 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2020, subject to the Reporting Person continuing to provide service through each such date.
F4 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
F5 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
F6 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.